Medtronic receives FDA approval for next-gen Micra leadless pacing systems

Medtronic announced it has received U.S. FDA approval of its Micra AV2 and Micra VR2, the next generation of its leadless pacemakers. "Our goal is to improve the patient experience by continuously reinventing our ground-breaking leadless pacemaker," said Robert C. Kowal, M.D., Ph.D., general manager, Cardiac Pacing Therapies within the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "Since inventing the first battery-operated cardiac pacemakers 65 years ago, Medtronic has transformed pacing technologies to benefit patients, including the nearly 200,000 patients globally who have received a Micra device so far."